Inhaled Antibiotic for Bronchiectasis Shows Benefit ... and Then It Doesn't | MedPage Today
Nebulized colistimethate sodium showed mixed results in bronchiectasis and Pseudomonas aeruginosa infections, with PROMIS-I showing reduced exacerbation rates (RR 0.61) and PROMIS-II showing no difference (RR 1.00). COVID-19 disruptions in PROMIS-II were identified as the cause for the differing outcomes. A meta-analysis supported colistimethate sodium's efficacy in reducing exacerbation rates (RR 0.65). Despite inconsistent trial results, inhaled antibiotics for bronchiectasis have received conditional endorsement in guidelines.
Related Clinical Trials
Reference News
Nebulized colistimethate sodium showed mixed results in bronchiectasis and Pseudomonas aeruginosa infections, with PROMIS-I showing reduced exacerbation rates (RR 0.61) and PROMIS-II showing no difference (RR 1.00). COVID-19 disruptions in PROMIS-II were identified as the cause for the differing outcomes. A meta-analysis supported colistimethate sodium's efficacy in reducing exacerbation rates (RR 0.65). Despite inconsistent trial results, inhaled antibiotics for bronchiectasis have received conditional endorsement in guidelines.